Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
Molecular Cancer Therapeutics
|
February 23, 2018
JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers
Sean P Pitroda, Melinda E Stack, Gene-Fu Liu, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
September 28, 2017
Fluorine-18 Fluoro-2-Deoxyglucose Positron Emission Tomography Uptake in the Superficial Temporal and Vertebral Arteries in Biopsy Positive Giant Cell Arteritis
Anthony Michael Sammel, Edward Hsiao, Leslie Schrieber, et al.
BJU International
|
April 29, 2022
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups
Matthew J Roberts, Mark D Chatfield, George Hruby, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 2, 2024
[<sup>18</sup>F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
David L Chan, Aimee R Hayes, Ioannis Karfis, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 13, 2008
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer
Ralph R Weichselbaum, Hemant Ishwaran, Taewon Yoon, et al.
Plos One
|
June 9, 2009
STAT1 pathway mediates amplification of metastatic potential and resistance to therapy
Nikolai N Khodarev, Paul Roach, Sean P Pitroda, et al.
British Journal of Cancer
|
November 26, 2022
Dual [<sup>68</sup>Ga]DOTATATE and [<sup>18</sup>F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
David L Chan, Aimee R Hayes, Ioannis Karfis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 3, 2019
3-Year Freedom from Progression After <sup>68</sup>Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial
Louise Emmett, Reuben Tang, Rohan Nandurkar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 16, 2026
[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial
David L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.
Lancet (London, England)
|
March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
Molecular Cancer Therapeutics
|
February 23, 2018
JAK2 Inhibitor SAR302503 Abrogates PD-L1 Expression and Targets Therapy-Resistant Non-small Cell Lung Cancers
Sean P Pitroda, Melinda E Stack, Gene-Fu Liu, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|
September 28, 2017
Fluorine-18 Fluoro-2-Deoxyglucose Positron Emission Tomography Uptake in the Superficial Temporal and Vertebral Arteries in Biopsy Positive Giant Cell Arteritis
Anthony Michael Sammel, Edward Hsiao, Leslie Schrieber, et al.
BJU International
|
April 29, 2022
Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups
Matthew J Roberts, Mark D Chatfield, George Hruby, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 2, 2024
[<sup>18</sup>F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
David L Chan, Aimee R Hayes, Ioannis Karfis, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 13, 2008
An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer
Ralph R Weichselbaum, Hemant Ishwaran, Taewon Yoon, et al.
Plos One
|
June 9, 2009
STAT1 pathway mediates amplification of metastatic potential and resistance to therapy
Nikolai N Khodarev, Paul Roach, Sean P Pitroda, et al.
British Journal of Cancer
|
November 26, 2022
Dual [<sup>68</sup>Ga]DOTATATE and [<sup>18</sup>F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
David L Chan, Aimee R Hayes, Ioannis Karfis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
November 3, 2019
3-Year Freedom from Progression After <sup>68</sup>Ga-PSMA PET/CT-Triaged Management in Men with Biochemical Recurrence After Radical Prostatectomy: Results of a Prospective Multicenter Trial
Louise Emmett, Reuben Tang, Rohan Nandurkar, et al.
European Journal of Cancer (Oxford, England : 1990)
|
May 16, 2026
[<sup>177</sup>Lu]Lu-DOTATATE PRRT and CAPTEM chemotherapy for pancreas and small bowel neuroendocrine tumours: The AGITG CONTROL NETS Multi-centre randomized trial
David L Chan, Katrin Marie Sjoquist, David Turner Ransom, et al.
Lancet (London, England)
|
March 27, 2020
Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study
Michael S Hofman, Nathan Lawrentschuk, Roslyn J Francis, et al.
Page
of 10